Impact of mandibular advancement devices on C‐reactive protein levels in patients with obstructive sleep apnea. (28th November 2014)

• Record Type: Journal Article
• Authors: Yalamanchali, Sreeya; Salapatas, Anna M.; Hwang, Michelle S.; Pott, Thomas R.; Lundgren, Mary E.; Joseph, Ninos J.; Friedman, Michael
• Is Part Of: Laryngoscope. Volume 125:Number 7(2015:Jul.)
• Page Start: 1733
• Page End: 1736
• Publication Date: 2014-11-28
• Subjects: Otolaryngology -- Periodicals; 617.51005
• DOI: 10.1002/lary.25061
• Languages: English
• ISSNs: 0023-852X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="lary25061-sec-0001" sec-type="section"> <title>Objectives/Hypothesis</title> <p>To determine the effect of treatment of obstructive sleep apnea (OSA) with custom‐made mandibular advancement devices (MADs) on C‐reactive protein (CRP) levels in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS).</p> </sec> <sec id="lary25061-sec-0002" sec-type="section"> <title>Study Design</title> <p>Case series with chart review.</p> </sec> <sec id="lary25061-sec-0003" sec-type="section"> <title>Methods</title> <p>Charts of consecutive patients fitted with custom‐made mandibular advancement devices for treatment of OSAHS between December 2011 and November 2012 were reviewed. Demographics such as age, sex, and body mass index (BMI) were collected. Prefitting and postfitting polysomnograms were reviewed. Pre‐ and posttreatment apnea–hypopnea index (AHI) and average O<sub>2</sub> saturation were compared. Only patients with documented CRP levels determined prior to mandibular advancement device fitting and again after improvement of OSAHS symptoms were included.</p> </sec> <sec id="lary25061-sec-0004" sec-type="section"> <title>Results</title> <p>Forty‐nine patients (77.6% male, age 47.4 ± 11.7 years, BMI 29.6 ± 5.0 kg/m<sup>2</sup>) were included in this study. Patients initially had elevated CRP levels (2.5 ± 1.8 mg/dl), which decreased significantly following use of their custom‐made mandibular advancement device (1.9 ± 1.3 mg/dl, <italic>P</italic> = 0.006) by approximately 24%. AHI decreased significantly from 33.3 ± 21.7 pretreatment to 12.1 ± 22.3 posttreatment (<italic>P</italic> < 0.001). Treatment with MADs reduced AHI by approximately 69.3%. Minimum oxygen saturation significantly improved from 85.1% ± 5.9 pretreatment to 90.7% ± 3.6 posttreatment (<italic>P</italic> < 0.001).</p> </sec> <sec id="lary25061-sec-0005" sec-type="section"> <title>Conclusion</title> <p>Treatment with custom‐made mandibular advancement devices significantly reduced elevated CRP levels in patients with mild to severe OSAHS. Therapy achieves reasonable response and cure rates in the observed patients with a significant reduction in AHI.</p> </sec> <sec id="lary25061-sec-0006" sec-type="section"> <title>Level of Evidence</title> <p>4. <italic>Laryngoscope</italic>, 125:1733–1736, 2015</p> </sec> </abstract>